The BNP test is an indispensable tool in modern cardiology, offering a rapid and objective evaluation of heart function. It is a simple blood test that measures the levels of proteins called natriuretic peptides (NPs), primarily B-type natriuretic peptide (BNP) and its precursor, N-terminal pro-B-type natriuretic peptide (NT-proBNP).
High levels of these peptides act as a chemical alarm, signaling that the heart is being subjected to excessive stress, volume overload, or pressure.
The most common application of the BNP test is in the diagnosis, severity assessment, and management of heart failure (HF)—a chronic condition where the heart struggles to pump enough blood to meet the body’s needs.
Elevated BNP test levels are often the missing link needed to confirm a heart failure diagnosis, especially when a patient presents with non-specific symptoms like shortness of breath.
This article will explain how these cardiac biomarkers are produced, what the key diagnostic thresholds are, and how clinicians use this information to empower you toward healthier heart function.
What Are Natriuretic Peptides (BNP and NT-proBNP)?
Natriuretic peptides (NPs) are a family of hormones the body uses to regulate blood volume, blood pressure, and fluid balance.
When the heart experiences stress, it releases these peptides to signal the kidneys and blood vessels to take action, a natural attempt to correct the overload on the heart. The two most clinically relevant natriuretic peptides for heart failure are:
- B-type Natriuretic Peptide (BNP): A biologically active hormone that directly promotes the excretion of salt and water (natriuresis and diuresis) and relaxes blood vessels (vasodilation) to lower blood pressure.
- N-terminal pro-B-type Natriuretic Peptide (NT-proBNP): An inactive fragment that is co-released with BNP.
Why Does the Heart Release BNP?
The primary stimulus for the synthesis and secretion of BNP and NT-proBNP is myocardial wall stress or stretch, especially within the heart’s main pumping chambers, the ventricles.
- Increased Workload: In heart failure, the ventricles cannot pump efficiently, causing blood to back up. This increases pressure and stretches the muscular walls of the chambers.
- Hormone Synthesis: In response to this mechanical stretch, cardiac muscle cells (cardiomyocytes) produce a precursor molecule called proBNP.
- Cleavage and Release: ProBNP is cleaved into two fragments as it is released: the active BNP and the inactive NT-proBNP.
The physiological goal is to counteract heart failure by causing the kidneys to excrete sodium and water, reducing the blood volume, and lowering resistance.
The Difference Between BNP and NT-proBNP
While both tests offer similar diagnostic information, differences exist in how they are measured:
Feature | BNP (B-type Natriuretic Peptide) | NT-proBNP (N-terminal pro-B-type Natriuretic Peptide) |
Biological Activity | Active hormone | Inactive fragment |
Half-Life | Shorter (Approx. 20 minutes) | Longer (Approx. 60–120 minutes) |
Plasma Concentration | Lower | Higher (often 2-10 times higher in HF patients) |
Excretion/Clearance | Cleared by the enzyme neprilysin | Primarily cleared by the kidneys (renal excretion) |
Drug Interference | Levels can be affected by Neprilysin Inhibitors (artificially elevates the result) | Levels are not affected by Neprilysin Inhibitors |
NT-proBNP’s stability and longer half-life often make it the preferred measurement. In patients taking Neprilysin Inhibitor drugs (like sacubitril), the NT-proBNP test must be used for accurate monitoring.
The BNP Test and Heart Failure Diagnosis
The primary utility of the BNP test is its highly effective use in a “rule-out” strategy for heart failure. A normal natriuretic peptide level makes the heart failure diagnosis highly unlikely, helping clinicians quickly distinguish heart failure-related shortness of breath from other causes, such as lung disease.
The AHA and ESC recommend the routine measurement of BNP or NT-proBNP in any patient presenting with signs or symptoms suggestive of heart failure, such as dyspnea (shortness of breath).
How the Test is Performed
The BNP test is a simple, non-fasting blood test requiring a blood sample drawn from a vein in the arm. It provides quick results to make acute clinical decisions.
BNP and NT-proBNP Cutoff Values for Heart Failure (ESC 2023)
Interpreting the BNP test relies on established cutoff values. These thresholds differ based on whether the patient is presenting with acute or chronic heart failure.
Acute Heart Failure Thresholds (In-Hospital Setting)
In the urgent setting, the goal is rapid rule-out.
Peptide | Level to Rule Out Acute Heart Failure |
BNP | <100 pg/mL or ng/L |
NT-proBNP | <300 pg/mL or ng/L |
Non-Acute/Chronic Heart Failure Thresholds (Outpatient Setting)
For patients evaluated in a clinic setting, lower thresholds are used for screening.
Peptide | Level Suggesting Need for Further Evaluation |
BNP | ≥35 pg/mL (or ng/L) |
NT-proBNP | ≥125 pg/mL (or ng/L) |
An NT-proBNP level of ≥125 pg/mL in a symptomatic patient strongly suggests the need for further cardiac evaluation, typically with an echocardiogram.
Age-Adjusted NT-proBNP Cutoffs for Acute HF:
The NT-proBNP threshold naturally increases with age. Age-adjusted thresholds are sometimes used to rule-in acute heart failure in older populations:
- Age < 50 years: ≥450 pg/mL
- Age 50–75 years: ≥900 pg/mL
- Age > 75 years: ≥1,800 pg/mL
Interpreting Your BNP Test Results
A BNP test result is always interpreted alongside the patient’s symptoms, medical history, and other diagnostic results. The magnitude of the elevation correlates with the severity of the heart failure.
What High BNP Levels Mean
Elevated natriuretic peptide levels (above the established cutoff) signify two major clinical facts:
- Presence of Heart Failure (Rule-In): Levels significantly above the diagnostic thresholds make the presence of heart failure highly probable.
- Increased Myocardial Wall Stress: The high peptides confirm that the heart muscle is currently being stretched or overloaded.
For patients with known heart failure, increasing levels often indicate decompensation (worsening of the condition) or a failure of current treatment to adequately manage fluid and pressure overload.
Factors That Can Affect BNP Levels Beyond Heart Failure
While primarily linked to heart failure, other medical conditions can also cause natriuretic peptides to rise:
Condition | Effect on BNP/NT-proBNP | Reason for Elevation |
Kidney Failure (Renal Dysfunction) | Elevated | Impaired kidney function reduces the clearance of NT-proBNP, leading to a build-up. |
Older Age | Slightly Elevated | Levels naturally increase over time. |
Pulmonary Hypertension / PE | Elevated | High pressure in the lung arteries causes strain on the right-side of the heart. |
Obesity | Lowered | Patients with high BMI often have paradoxically lower levels, potentially due to altered clearance. |
A high BNP test result is a strong indicator of heart strain, but it is not specific only to heart failure. Renal dysfunction is a particularly important factor to consider when interpreting an elevated NT-proBNP level.
The Role of BNP in Management and Prognosis
Serial measurement of BNP or NT-proBNP is useful for guiding heart failure treatment and assessing the long-term outlook (prognosis).
Monitoring Treatment Effectiveness
Successful therapy should lead to a measurable drop in natriuretic peptide levels.
- Biomarker-Guided Therapy: Some strategies use NT-proBNP levels to actively guide the upward titration of heart failure medications (e.g., aiming for a target reduction).
- Significance of Falling Levels: A drop in NT-proBNP suggests that therapy is working to relieve volume overload and improve cardiac function.
- Significance of Rising Levels: An unexpected increase should prompt a review for progressive disease, non-adherence to medication or diet, or a complication.
Predicting Outcomes (Prognosis)
Natriuretic peptides are powerful predictors of future cardiovascular events and mortality.
- Risk Stratification: High baseline levels of BNP or NT-proBNP are strongly associated with an increased risk of future hospitalization and cardiovascular death.
- Persistent Elevation: Patients whose peptide levels remain significantly elevated despite optimal medical therapy are classified as being at a higher risk and may require more intensive follow-up or consideration for advanced therapies.
Key Takeaways on the BNP Test
- Rule-Out Power: A low NT-proBNP level makes the diagnosis of heart failure highly improbable.
- Indicator of Strain: Elevated levels directly signal myocardial wall stress and volume overload.
- Diagnostic Thresholds: Interpretation relies on specific cutoff values (e.g., ≥125 pg/mL for chronic heart failure evaluation with NT-proBNP).
- Management Guide: Measuring natriuretic peptides helps track the effectiveness of treatment; falling levels indicate successful management.
- Prognostic Value: Persistently high levels indicate a higher risk and require intensive follow-up.
This blood test ensures that patients with suspected heart failure receive timely and accurate evaluation, leading to tailored treatment strategies that empower them toward better long-term heart health.
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(30):2828–2836. Available from: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Focused-Update-on-Heart-Failure-Guidelines
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032. Available from: https://eguideline.guidelinecentral.com/i/1461930/10
- Januzzi JL, Chen-Tournoux AA, Moe G. Amino-terminal Pro-B-type Natriuretic Peptide testing for the diagnosis or exclusion of acute heart failure in patients with acute dyspnea: the ICON-RELOADED study. Circulation. 2010;121(19):2100–2107. Available from: https://acutecaretesting.org/en/articles/choosing-cut-offs-for-nt-probnp
- Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim H-N, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011 Oct 25;58(18):1881-9. Available from: https://pubmed.ncbi.nlm.nih.gov/22018299/
- McCullough PA, Peacock WF. Natriuretic peptides as a prognostic marker and therapeutic target in heart failure. Postgrad Med J. 2006;82(964):104–109. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1860769/
- Saha K, Ahmed B. Assessment of the diagnostic value of NT-proBNP in heart failure with preserved ejection fraction. Br J Cardiol. 2204;31(1):50-54. Available from: https://bjcardio.co.uk/2024/01/assessment-of-the-diagnostic-value-of-nt-probnp-in-heart-failure-with-preserved-ejection-fraction/
Frequently Asked Questions (FAQs)
As people age, NT-proBNP levels tend to naturally increase. Clinicians often use age-adjusted cutoff values for older patients to prevent over-diagnosing heart failure based on a slightly elevated result that may be normal for their age group.
Yes, a high natriuretic peptide level indicates heart strain but is not specific only to heart failure. Other causes include kidney dysfunction (which slows NT-proBNP clearance), severe infections (sepsis), high pressure in the lung arteries (pulmonary hypertension), and irregular heart rhythms (atrial fibrillation).
NT-proBNP is often favored because it is more stable in the blood sample and its levels are not artificially affected by some newer, common heart failure medications (Neprilysin Inhibitors), which can interfere with and elevate BNP test results.
A significant drop in BNP or NT-proBNP levels is a positive sign that therapy is successfully reducing heart strain and fluid overload. However, heart failure is a chronic condition. The drop confirms successful control, not a permanent cure, and ongoing adherence to the treatment plan remains essential.
The BNP test indicates wall stress and fluid overload, used for diagnosing heart failure. The troponin test measures proteins released when the heart muscle is damaged (necrosis) and is primarily used to diagnose an acute event like a heart attack.
